This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease


Weiner, Michael W., Sadowsky, Carl, Saxton, Judith, Hofbauer, Robert K., Graham, Stephen M., Yu, Sung Yun, Li, Shaoyi, Hsu, Hai-An, Suhy, Joyce, Fridman, Moshe, Perhach, James L.


Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, Volume: 7, No.: 4, Pages.: 425-435

Year of Publication



Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an open-label period of add-on memantine treatment (weeks: 25-48). The patients underwent magnetic resonance imaging at weeks 0 (baseline), 24 (immediately before memantine initiation), and 48 (endpoint), and a battery of neuropsychological tests at weeks 0, 24, 28, 36, and 48. The primary outcome measure was the annualized rate of change (%) in total brain volume (TBV) between the two study periods. Data were analyzed using paired t-tests.; Results: There were no statistically significant differences in the rates of change in TBV, ventricular volume, or left hippocampal volume between the study periods; however, the memantine treatment period was associated with a significantly slower right hippocampal atrophy (-5.5% ± 12.0% vs -10.8% ± 7.2%; P = .038). Memantine treatment was also associated with superior performances on the Boston Naming Test (P = .034) and the Trail Making Test, Part B (P = .001), but also with a higher number of errors (i.e., repetitions and intrusions) on the California Verbal Learning Test. Memantine was found to be safe and well tolerated.; Conclusions: In this study, no difference in the rates of TBV change between the two periods was observed; however, memantine treatment was found to be associated with slowing of right hippocampal atrophy, and with improvement on one test of executive functioning as well as a test of confrontation naming ability. Trials using structural magnetic resonance imaging and a delayed-start design may be a feasible option for the assessment of treatments for AD.; Copyright © 2011 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Weiner_2011, doi = {10.1016/j.jalz.2010.09.003}, url = {}, year = 2011, month = {jul}, publisher = {Elsevier {BV}}, volume = {7}, number = {4}, pages = {425--435}, author = {Michael W. Weiner and Carl Sadowsky and Judith Saxton and Robert K. Hofbauer and Stephen M. Graham and Sung Yun Yu and Shaoyi Li and Hai-An Hsu and Joyce Suhy and Moshe Fridman and James L. Perhach}, title = {Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


aged, aged, 80 and over, alzheimer disease, brain, cholinesterase inhibitors, cognition disorders, complications, drug effects, drug therapy, drug therapy combination, etiology, excitatory amino acid antagonists, female, humans, magnetic resonance imaging, male, memantine, neuropsychological tests, pathology, statistics nonparametric, therapeutic use, total, treatment outcome, volume

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes

Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime